HomeAI · summaries
Storia in 2 fonti
China’s biotech boom: RAS-targeted drugs challenge US dominance
The rapid development of China’s RAS-targeted cancer drugs could reshape global oncology and unlock the country’s undervalued biotech firms.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
scmp.com
China’s biotech boom: RAS-targeted drugs challenge US dominance
The rapid development of China’s RAS-targeted cancer drugs could reshape global oncology and unlock the country’s undervalued biotech firms.
- ·
endpoints.news
'We're paranoid.' As China biotech competition heats up, American drugmakers get more secretive
US biotechs turn tight-lipped on gene targets and pipelines as China's fast-follower threat intensifies, 20+ founders and investors tell Endpoints.